Botulinum toxin plus conservative treatment vs conservative treatment
Pain · children with ITW gait
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
207 questions · 244 findings · 20 reviews · Headline outcomes only
No studies found 53 · 21.7%GRADE not reported 6 · 2.5%Very low 50 · 20.5%Low 39 · 16%Moderate 69 · 28.3%High 27 · 11.1%
Botulinum toxin plus conservative treatment vs conservative treatment
Recurrence of ITW post‐treatment Assessed by improvement in toe walking based on Gait Analysis Classification An increase indicates improvement (an improvement indicated by a change in downgrading of the severe or 3, moderate or 2, and mild or 1 c... · children with ITW gait
1 finding from 1 review
- no estimate extracted1 study · 46 participantsVery low
Botulinum toxin plus conservative treatment vs conservative treatment
Adverse events · children with ITW gait
It is very uncertain whether botulinum toxin plus conservative treatment changes adverse events compared with conservative treatment only (very low certainty).
1 finding from 1 review
- no estimate extracted1 study · 47 participantsVery low
Botulinum toxin A (with and without casting) vs placebo (with and without casting)
Sensory functions and pain · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for managing skeletal muscle spasticity following traumatic brain injury 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Botulinum toxin A (with and without casting) vs placebo (with and without casting)
Neuromusculoskeletal and movement‐related functions at 12 weeks (measured by ankle dorsiflexion) · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
1 finding from 1 review
- Interventions for managing skeletal muscle spasticity following traumatic brain injury 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 47 participantsVery low
Botulinum toxin A (with and without casting) vs placebo (with and without casting)
General tasks and demands · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for managing skeletal muscle spasticity following traumatic brain injury 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Botulinum toxin A (with and without casting) vs placebo (with and without casting)
Mobility · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for managing skeletal muscle spasticity following traumatic brain injury 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Botulinum toxin A (with and without casting) vs placebo (with and without casting)
Self‐care · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for managing skeletal muscle spasticity following traumatic brain injury 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Botulinum toxin A (with and without casting) vs placebo (with and without casting)
Spasticity at 4‐12 weeks (measured by both Modified Ashworth Scale, 0‐5, at 12 weeks and Tardieu Scale, 0‐5, at 4 weeks) · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
1 finding from 1 review
- Interventions for managing skeletal muscle spasticity following traumatic brain injury 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 47 participantsVery low
Botulinum toxin A (with and without casting) vs placebo (with and without casting)
Adverse events · adults with traumatic brain injury with spasticity in their arms (1 study) or calves (1 study)
1 finding from 1 review
- Interventions for managing skeletal muscle spasticity following traumatic brain injury 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 47 participantsVery low
Botulinum neurotoxin B vs placebo
Overall cervical dystonia improvement as · adults with cervical dystonia
1 finding from 1 review
- no estimate extracted3 studies · 316 participantsModerate
Botulinum neurotoxin B vs placebo
Withdrawals due to adverse events · adults with cervical dystonia
Botulinum neurotoxin B showed no clear difference in proportion of withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.88 [0.19, 4.06]4 studies · 440 participantsLow
Botulinum neurotoxin B vs placebo
Cervical dystonia‐specific pain · adults with cervical dystonia
1 finding from 1 review
- no estimate extracted2 studies · 207 participantsLow
Botulinum neurotoxin B vs placebo
Subjective change as assessed by the patient at week 4 · adults with cervical dystonia
1 finding from 1 review
- no estimate extracted3 studies · 316 participantsHigh
Botulinum neurotoxin B vs placebo
Proportion of participants with adverse events · adults with cervical dystonia
It is very uncertain whether botulinum neurotoxin B changes proportion of participants with adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.09 [0.97, 1.23]2 studies · 186 participantsVery low
Botulinum neurotoxin B vs placebo
Adverse effects: dry mouth · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dry mouth compared with placebo (high certainty).
1 finding from 1 review
- RR 7.65 [2.75, 21.32]4 studies · 438 participantsHigh
Botulinum neurotoxin B vs placebo
Dysphagia · adults with cervical dystonia
Botulinum neurotoxin B leads to higher adverse events: dysphagia compared with placebo (high certainty).
1 finding from 1 review
- RR 6.78 [2.42, 19.05]4 studies · 438 participantsHigh
Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo
Partcipant assessment of success · glabellar lines
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).
1 finding from 1 review
- RR 19.45 [8.6, 43.99]4 studies · 575 participantsModerate
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo
Duration of treatment effect · glabellar lines
1 finding from 1 review
- no estimate extracted1 study · 100 participantsModerate
Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo
Major adverse events · glabellar lines
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- OR 3.62 [1.5, 8.74]8 studies · 1390 participantsModerate